{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:51:36Z","timestamp":1792223496438,"version":"4.4.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"EORTC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.11.036","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T02:10:16Z","timestamp":1670897416000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-429X","authenticated-orcid":false,"given":"Marjanka K.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5820-997X","authenticated-orcid":false,"given":"Jennifer E.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Br\u00e9dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-0902","authenticated-orcid":false,"given":"Jana","family":"de Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2444-3247","authenticated-orcid":false,"given":"Douglas F.","family":"Easton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte V.","family":"Offersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorita","family":"Poulakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel T.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-9427","authenticated-orcid":false,"given":"Francesco","family":"Sardanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Schmutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Spanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel J.T.","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ejca.2022.11.036_bib1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2020.22414","article-title":"Risk-reducing mastectomy","volume":"325","author":"Jatoi","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000485830","article-title":"Prophylactic surgery: for whom, when and how?","volume":"12","author":"Mau","year":"2017","journal-title":"Breast Care (Basel)"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib3","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","article-title":"Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks","volume":"23","author":"Boughey","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib4","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1245\/s10434-016-5408-8","article-title":"Contralateral prophylactic mastectomy consensus statement from the American Society of Breast Surgeons: additional considerations and a framework for shared decision making","volume":"23","author":"Boughey","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12957-015-0638-y","article-title":"The Manchester guidelines for contralateral risk-reducing mastectomy","volume":"13","author":"Basu","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"9\u201310","key":"10.1016\/j.ejca.2022.11.036_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00508-019-1468-7","article-title":"Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition: consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology","volume":"131","author":"Bjelic-Radisic","year":"2019","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.ejca.2022.11.036_bib8","author":"National Comprehensive Cancer Network"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/SLA.0000000000002309","article-title":"Indications for contralateral prophylactic mastectomy: a consensus statement using modified Delphi methodology","volume":"267","author":"Wright","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2022.11.036_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41416-021-01417-7","article-title":"The risk of contralateral breast cancer: a SEER-based analysis","volume":"125","author":"Giannakeas","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pec.2021.04.033","article-title":"The implementation of a decision aid for women with early-stage breast cancer considering contralateral prophylactic mastectomy: a pilot study","volume":"105","author":"Jansen","year":"2022","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.ejca.2022.11.036_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.breast.2021.02.003","article-title":"Contralateral prophylactic mastectomy: a narrative review of the evidence and acceptability","volume":"56","author":"Scheepens","year":"2021","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.036_bib13","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S1470-2045(13)70047-0","article-title":"Contralateral risk-reducing mastectomy in sporadic breast cancer","volume":"14","author":"Murphy","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13058-014-0442-6","article-title":"The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services","volume":"16","author":"Evans","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2022.11.036_bib15","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1111\/1475-6773.12774","article-title":"Trends in use of risk-reducing mastectomy in a context of celebrity decisions and media coverage: an observational study in the United States and Australia","volume":"53","author":"Mao","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.ejca.2022.11.036_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3166\/pson-2019-0097","article-title":"Comment r\u00e9pondre aux demandes de mastectomie prophylactique controlat\u00e9rale apr\u00e8s un cancer du sein hors pr\u00e9disposition g\u00e9n\u00e9tique? Perspectives \u00e9thiques et cliniques","volume":"13","author":"Couillet","year":"2019","journal-title":"Psycho-Oncologie"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.036_bib17","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1245\/s10434-016-5253-9","article-title":"Surgeons' perspectives of contralateral prophylactic mastectomy","volume":"23","author":"Bellavance","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.7326\/0003-4819-159-6-201309170-00003","article-title":"Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey","volume":"159","author":"Rosenberg","year":"2013","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamasurg.2013.5689","article-title":"Social and clinical determinants of contralateral prophylactic mastectomy","volume":"149","author":"Hawley","year":"2014","journal-title":"JAMA Surg"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.036_bib20","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.2014.10707","article-title":"Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011","volume":"312","author":"Kurian","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-013-2745-1","article-title":"Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002","volume":"142","author":"Yao","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/SLA.0000000000001698","article-title":"Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer","volume":"265","author":"Wong","year":"2017","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.036_bib23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/jamasurg.2017.0115","article-title":"State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004-2012","volume":"152","author":"Nash","year":"2017","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib24","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1245\/s10434-014-3956-3","article-title":"Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer","volume":"21","author":"Pesce","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10549-020-05965-z","article-title":"Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study","volume":"185","author":"Findlay-Shirras","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-021-06397-z","article-title":"Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016","volume":"190","author":"Yang","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2022.11.036_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jss.2020.12.057","article-title":"Trends in contralateral prophylactic mastectomy utilization for small unilateral breast cancer","volume":"262","author":"Baskin","year":"2021","journal-title":"J Surg Res"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jamcollsurg.2015.03.033","article-title":"Variation in contralateral prophylactic mastectomy rates according to racial groups in young women with breast cancer, 1998 to 2011: a report from the National Cancer Database","volume":"221","author":"Grimmer","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.036_bib29","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1200\/JCO.2008.20.1681","article-title":"Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ","volume":"27","author":"Tuttle","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijsu.2017.12.022","article-title":"Mastectomy for risk reduction or symmetry in women without high risk gene mutation: a review","volume":"50","author":"Kenny","year":"2018","journal-title":"Int J Surg"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.036_bib31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejso.2011.12.014","article-title":"Increasing rates of contralateral prophylactic mastectomy \u2013 a trend made in USA?","volume":"38","author":"G\u00fcth","year":"2012","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2018.02.003","article-title":"Mastectomy patterns, but not rates, are changing in the treatment of early breast cancer. Experience of a single European institution on 2315 consecutive patients","volume":"39","author":"Fancellu","year":"2018","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib33","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1038\/s41598-021-82654-x","article-title":"The Angelina Jolie effect: contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer","volume":"11","author":"Basu","year":"2021","journal-title":"Sci Rep"},{"issue":"2 Suppl","key":"10.1016\/j.ejca.2022.11.036_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.21614\/chirurgia.116.2Suppl.S73","article-title":"Contralateral prophylactic mastectomy in patients with breast cancer","volume":"116","author":"Noditi","year":"2021","journal-title":"Chirurgia (Bucur)"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.036_bib35","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","article-title":"Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group","volume":"26","author":"Metcalfe","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.036_bib37","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-011-1914-x","article-title":"Perceptions of contralateral breast cancer: an overestimation of risk","volume":"18","author":"Abbott","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib38","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1245\/s10434-012-2525-x","article-title":"Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age","volume":"19","author":"Fisher","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/pon.5379","article-title":"Contralateral prophylactic mastectomy for unilateral breast cancer in women at average risk: systematic review of patient reported outcomes","volume":"29","author":"Srethbhakdi","year":"2020","journal-title":"Psychooncology"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamasurg.2016.4749","article-title":"Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer","volume":"152","author":"Jagsi","year":"2017","journal-title":"JAMA Surg"},{"issue":"13","key":"10.1016\/j.ejca.2022.11.036_bib41","doi-asserted-by":"crossref","first-page":"8752","DOI":"10.1245\/s10434-021-10426-y","article-title":"Surgical decision-making surrounding contralateral prophylactic mastectomy: comparison of treatment goals, preferences, and psychosocial outcomes from a multicenter survey of breast cancer patients","volume":"28","author":"Lizarraga","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib42","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/pon.6013","article-title":"Emotion and contralateral prophylactic mastectomy: a prospective study into surgical decision-making","volume":"31","author":"Krasniak","year":"2022","journal-title":"Psychooncology"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14737140.2020.1732213","article-title":"Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients","volume":"20","author":"Montagna","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib44","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/bcr3369","article-title":"The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study","volume":"14","author":"Rhiem","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","article-title":"Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers","volume":"34","author":"van den Broek","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2022.11.036_bib46","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2022.11.036_bib47","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1054\/bjoc.2000.1239","article-title":"Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer","volume":"83","author":"Verhoog","year":"2000","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.036_bib49","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"10.1016\/j.ejca.2022.11.036_bib50","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Graeser","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.036_bib51","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ijc.32396","article-title":"German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Breast cancer risk in BRCA1\/2 mutation carriers and noncarriers under prospective intensified surveillance","volume":"146","author":"Engel","year":"2020","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","article-title":"Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers","volume":"93","author":"Van Sprundel","year":"2005","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib53","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.11.036_bib54","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","article-title":"Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer","volume":"140","author":"Evans","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.036_bib56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.suc.2018.03.004","article-title":"Breast cancer genetics and indications for prophylactic mastectomy","volume":"98","author":"Krontiras","year":"2018","journal-title":"Surg Clin North Am"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib57","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/annonc\/mdy515","article-title":"Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer","volume":"30","author":"Evron","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib58","article-title":"Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early-stage breast cancer","author":"Evron","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-020-1247-4","article-title":"Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Mavaddat","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.036_bib60","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41436-021-01198-7","article-title":"The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant","volume":"23","author":"Lakeman","year":"2021","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","article-title":"Clinical implications of germline mutations in breast cancer: TP53","volume":"167","author":"Schon","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib62","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.11.036_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2018.11.005","article-title":"Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis","volume":"44","author":"Akdeniz","year":"2019","journal-title":"Breast"},{"issue":"35","key":"10.1016\/j.ejca.2022.11.036_bib64","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","article-title":"CHEK2\u22171100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer","volume":"30","author":"Weischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajhg.2020.09.001","article-title":"Breast cancer polygenic risk score and contralateral breast cancer risk","volume":"107","author":"Kramer","year":"2020","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib66","first-page":"403","article-title":"The impact of lifestyle and reproductive factors on the risk of a second new\u00a0primary cancer in the contralateral breast: a systematic review and meta-analysis","volume":"31","author":"Akdeniz","year":"2020","journal-title":"Cancer Causes Control"},{"issue":"9114","key":"10.1016\/j.ejca.2022.11.036_bib67","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.036_bib68","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/djz010","article-title":"The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype","volume":"111","author":"Kramer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2022.11.036_bib69","series-title":"New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000","first-page":"181","article-title":"New malignancies following breast cancer","author":"Curtis","year":"2006"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/jcm7060133","article-title":"Patterns of occurrence and outcomes of contralateral breast cancer: analysis of SEER data","volume":"7","author":"Xiong","year":"2018","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.036_bib71","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/ijc.33501","article-title":"Race, ethnicity and risk of second primary contralateral breast cancer in the United States","volume":"148","author":"Watt","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-010-1324-y","article-title":"Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer","volume":"129","author":"Schairer","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.036_bib73","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1634\/theoncologist.2011-0022","article-title":"Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer","volume":"16","author":"Brewster","year":"2011","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.036_bib74","first-page":"CD002748","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","volume":"4","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib75","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jamasurg.2020.6664","article-title":"Bilateral mastectomy in women with unilateral breast cancer: a review","volume":"156","author":"Lim","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejca.2022.11.036_bib76","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.ejso.2015.02.017","article-title":"A multidisciplinary team approach minimises prophylactic mastectomy rates","volume":"41","author":"Leff","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib77","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-016-4039-x","article-title":"A model for individualized risk prediction of contralateral breast cancer","volume":"161","author":"Chowdhury","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib78","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-018-4763-5","article-title":"Validation of a personalized risk prediction model for contralateral breast cancer","volume":"170","author":"Chowdhury","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-019-1221-1","article-title":"Prediction and clinical utility of a contralateral breast cancer risk model","volume":"21","author":"Giardiello","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.036_bib81","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib82","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk Tool\u2013a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib83","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-012-1958-z","article-title":"Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO","volume":"133","author":"Biswas","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ejca.2022.11.036_bib85","unstructured":"Giardiello D, Hooning MJ, Hauptmannet M, et\u00a0al. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in \u223c200,000 patients. Unpublished results."},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib86","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-020-05611-8","article-title":"Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts","volume":"181","author":"Giardiello","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib87","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/djz177","article-title":"Performance of breast cancer risk-assessment models in a large mammography cohort","volume":"112","author":"McCarthy","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.breast.2015.02.002","article-title":"Overall survival according to type of surgery in young (\u226440 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy","volume":"24","author":"Vila","year":"2015","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.036_bib89","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/j.ijrobp.2011.02.060","article-title":"Early-stage young breast cancer patients: impact of local treatment on survival","volume":"81","author":"Bantema-Joppe","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.036_bib90","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/cncr.27795","article-title":"Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status","volume":"119","author":"Hwang","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib91","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ijc.31034","article-title":"Breast conserving therapy and mastectomy revisited: breast cancer-specific survival and the influence of prognostic factors in 129,692 patients","volume":"142","author":"Lagendijk","year":"2018","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.036_bib92","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2022.11.036_bib93","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.036_bib94","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(16)30067-5","article-title":"10-year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study","volume":"17","author":"van Maaren","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib95","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2021.02.001","article-title":"Combined breast conservation therapy versus mastectomy for BRCA mutation carriers \u2013 a systematic review and meta-analysis","volume":"56","author":"Davey","year":"2021","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib96","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annonc.2021.11.014","article-title":"Outcome without any adjuvant systemic treatment in stage I ER+\/HER2- breast cancer patients included in the MINDACT trial","volume":"33","author":"Lopes Cardozo","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.036_bib97","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ejso.2016.04.054","article-title":"Contralateral risk reducing mastectomy in patients with sporadic breast cancer. Benefits and hazards","volume":"42","author":"Boccardo","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib98","unstructured":"European Commission Initiative on Breast Cancer. Planning surgical treatment. Available at: https:\/\/healthcare-quality.jrc.ec.europa.eu\/european-breast-cancer-guidelines\/surgical-planning; 2021. [Accessed 24 April 2022]."},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib99","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ijc.28014","article-title":"Optimal age to start preventive measures in women with BRCA1\/2 mutations or high familial breast cancer risk","volume":"133","author":"Tilanus-Linthorst","year":"2013","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2022.11.036_bib100","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ejca.2010.02.015","article-title":"Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group","volume":"46","author":"Sardanelli","year":"2010","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib101","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.6004\/jnccn.2009.0072","article-title":"The role of MRI in breast cancer screening","volume":"7","author":"Lehman","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib102","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1186\/s12885-017-3693-7","article-title":"The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review","volume":"17","author":"Cree","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib103","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10238-019-00598-z","article-title":"Diagnostic value of seven biomarkers for breast cancer: an overview with evidence mapping and indirect comparisons of diagnostic test accuracy","volume":"20","author":"Gao","year":"2020","journal-title":"Clin Exp Med"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib104","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1200\/OP.20.00571","article-title":"Utilization, timing, and outcomes of BRCA genetic testing among women with newly diagnosed breast cancer from a national commercially insured population: the ABOARD study","volume":"17","author":"Armstrong","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.036_bib105","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1245\/s10434-021-09855-6","article-title":"Frequency of contralateral prophylactic mastectomy in breast cancer patients with a negative BRCA1 and BRCA2 rapid genetic test result","volume":"28","author":"Metcalfe","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.036_bib106","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000511136","article-title":"Survey on physicians' knowledge and training needs in genetic counseling in Germany","volume":"16","author":"Dick","year":"2021","journal-title":"Breast Care (Basel)"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib107","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/PRS.0000000000007237","article-title":"Complications of contralateral prophylactic mastectomy: do they delay adjuvant therapy?","volume":"146","author":"Sharabi","year":"2020","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib108","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/SLA.0b013e3181c3c36d","article-title":"Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer","volume":"251","author":"Kaas","year":"2010","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib110","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/bcr2464","article-title":"PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer","volume":"12","author":"Wishart","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib111","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-019-05182-3","article-title":"What does risk of future cancer mean to breast cancer patients?","volume":"175","author":"Kaiser","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.ejca.2022.11.036_bib112","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/jnci\/94.20.1564","article-title":"Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy","volume":"94","author":"Metcalfe","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2022.11.036_bib113","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.20.02239","article-title":"Addressing the dilemma of contralateral prophylactic mastectomy with behavioral science","volume":"39","author":"Sacks","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2022.11.036_bib114","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2018.78.6442","article-title":"Prospective study of psychosocial outcomes of having contralateral prophylactic mastectomy among women with nonhereditary breast cancer","volume":"36","author":"Parker","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2022.11.036_bib115","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1001\/jama.2021.1647","article-title":"Surgery for breast cancer prevention","volume":"325","author":"Jatoi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2022.11.036_bib116","first-page":"1","article-title":"Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know","volume":"90","author":"Franceschini","year":"2019","journal-title":"Ann Ital Chir"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib117","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10549-017-4123-x","article-title":"Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1\/2 mutation noncarriers with newly diagnosed breast cancer","volume":"162","author":"Hamilton","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"10.1016\/j.ejca.2022.11.036_bib118","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1200\/JCO.21.02782","article-title":"Tools for contralateral prophylactic mastectomy decision making","volume":"40","author":"Gail","year":"2022","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2022.11.036_bib119","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/jnci\/85.17.1407","article-title":"Silicone controversy: a survey of women with breast cancer and silicone implants","volume":"85","author":"Winer","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.036_bib120","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.ejso.2021.05.036","article-title":"Biological and synthetic mesh assisted breast reconstruction procedures: joint guidelines from the Association of Breast Surgery and the British Association of Plastic, Reconstructive and Aesthetic Surgeons","volume":"47","author":"Whisker","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib121","unstructured":"Food and Drugs Administration. Risks and complications of breast implants. Available at: https:\/\/www.fda.gov\/medical-devices\/breast-implants\/risks-and-complications-breast-implants; 2022. [Accessed 18 October 2022]."},{"issue":"13","key":"10.1016\/j.ejca.2022.11.036_bib122","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1245\/s10434-013-3108-1","article-title":"Operative risks associated with contralateral prophylactic mastectomy: a single institution experience","volume":"20","author":"Miller","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib123","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/SLA.0000000000001840","article-title":"Tradeoffs associated with contralateral prophylactic mastectomy in women choosing breast reconstruction: results of a prospective multicenter cohort","volume":"266","author":"Momoh","year":"2017","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib124","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1245\/s10434-016-5753-7","article-title":"Long-term satisfaction and body image after contralateral prophylactic mastectomy","volume":"24","author":"Anderson","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib125","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1245\/s10434-013-3116-1","article-title":"Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: an analysis of the NSQIP database","volume":"20","author":"Osman","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.036_bib126","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1245\/s10434-015-4628-7","article-title":"The effect of contralateral prophylactic mastectomy on perioperative complications in women undergoing immediate breast reconstruction: a NSQIP analysis","volume":"22","author":"Silva","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib127","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1245\/s10434-017-5983-3","article-title":"Contralateral prophylactic mastectomy with immediate breast reconstruction increases healthcare utilization and cost","volume":"24","author":"Boughey","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib128","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.surg.2018.05.044","article-title":"Complications in patients with unilateral breast cancer who undergo contralateral prophylactic mastectomy versus unilateral mastectomy","volume":"164","author":"Huang","year":"2018","journal-title":"Surgery"},{"issue":"1s Suppl 1","key":"10.1016\/j.ejca.2022.11.036_bib129","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/SAP.0000000000002802","article-title":"Is It worth the risk? Contralateral prophylactic mastectomy with immediate bilateral breast reconstruction","volume":"87","author":"Chadab","year":"2021","journal-title":"Ann Plast Surg"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10549-020-05681-8","article-title":"Sensory profiles in women with neuropathic pain after breast cancer surgery","volume":"182","author":"Mustonen","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"10.1016\/j.ejca.2022.11.036_bib131","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1200\/JCO.2005.09.233","article-title":"Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance","volume":"23","author":"Frost","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib132","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/pon.4683","article-title":"\u201cI don't want to take chances.\u201d: a qualitative exploration of surgical decision making in young breast cancer survivors","volume":"27","author":"Rosenberg","year":"2018","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib133","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1897-4287-7-6","article-title":"Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy","volume":"7","author":"Tan","year":"2009","journal-title":"Hered Cancer Clin Pract"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib134","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.clbc.2017.09.010","article-title":"Assessing the effect of lifetime contralateral breast cancer risk on the selection of contralateral prophylactic mastectomy for unilateral breast cancer","volume":"18","author":"Hegde","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2022.11.036_bib135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.amjsurg.2018.11.040","article-title":"Factors associated with decision to undergo contralateral prophylactic mastectomy versus unilateral mastectomy","volume":"218","author":"Huang","year":"2019","journal-title":"Am J Surg"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib136","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1245\/s10434-019-07559-6","article-title":"Physician knowledge of breast cancer recurrence and contralateral breast cancer risk is associated with increased recommendations for contralateral prophylactic mastectomy: a survey of physicians at NAPBC-accredited centers","volume":"26","author":"Kantor","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.11.036_bib137","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1245\/s10434-021-09928-6","article-title":"Longitudinal study of psychosocial outcomes following surgery in women with unilateral nonhereditary breast cancer","volume":"28","author":"Lim","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2022.11.036_bib138","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1200\/JCO.19.00572","article-title":"Effect of psychological intervention on fear of cancer recurrence: a systematic review and meta-analysis","volume":"37","author":"Tauber","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ejca.2022.11.036_bib139","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0960-9776(09)70282-6","article-title":"Should the use of contralateral prophylactic mastectomy be increasing as it is?","volume":"18","author":"Wood","year":"2009","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12905-017-0366-2","article-title":"Motivations for contralateral prophylactic mastectomy as a function of socioeconomic status","volume":"17","author":"Baptiste","year":"2017","journal-title":"BMC Womens Health"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib141","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bjps.2019.11.026","article-title":"Contralateral prophylactic mastectomy (CPM) and the clinical consultation: a snapshot of UK healthcare professionals' views and experiences","volume":"73","author":"Williams","year":"2020","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.036_bib142","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1177\/1049732314557085","article-title":"Redefining risk and benefit: understanding the decision to undergo contralateral prophylactic mastectomy","volume":"25","author":"Rendle","year":"2015","journal-title":"Qual Health Res"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib143","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pon.4955","article-title":"Reframing the conversation about contralateral prophylactic mastectomy: preparing women for postsurgical realities","volume":"28","author":"Bloom","year":"2019","journal-title":"Psychooncology"},{"issue":"17","key":"10.1016\/j.ejca.2022.11.036_bib144","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1016\/j.ejca.2012.04.023","article-title":"Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image","volume":"48","author":"Unukovych","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/pon.4448","article-title":"The psychosocial impact of contralateral risk reducing mastectomy (CRRM) on women: a rapid review","volume":"27","author":"Collins","year":"2018","journal-title":"Psychooncology"},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib146","doi-asserted-by":"crossref","first-page":"e1341","DOI":"10.1097\/GOX.0000000000001341","article-title":"Personality traits as predictors of quality of life and body image after breast reconstruction","volume":"5","author":"Juhl","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib147","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s10434-999-0542-1","article-title":"Issues of regret in women with contralateral prophylactic mastectomies","volume":"6","author":"Montgomery","year":"1999","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.11.036_bib148","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/pon.4830","article-title":"The development of a template for psychological assessment of women considering risk-reducing or contralateral prophylactic mastectomy: a national Delphi consensus study","volume":"27","author":"Braude","year":"2018","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib149","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamasurg.2017.3415","article-title":"Surgeon influence on\u00a0variation in receipt of contralateral prophylactic mastectomy\u00a0for women with breast cancer","volume":"153","author":"Katz","year":"2018","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7314\/APJCP.2013.14.1.539","article-title":"Factors predictive of treatment by Australian breast surgeons of invasive female breast cancer by mastectomy rather than breast conserving surgery","volume":"14","author":"Roder","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"10.1016\/j.ejca.2022.11.036_bib151","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamasurg.2017.0458","article-title":"Patient reactions to surgeon recommendations about contralateral prophylactic mastectomy for treatment of breast cancer","volume":"152","author":"Katz","year":"2017","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib152","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3747\/co.26.4689","article-title":"Patient decision aid for contralateral prophylactic mastectomy for use in the consultation: a feasibility study","volume":"26","author":"Squires","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2022.11.036_bib153","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3332\/ecancer.2019.914","article-title":"The role of emotions in cancer patients' decision-making","volume":"13","author":"Mazzocco","year":"2019","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib154","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1037\/a0036834","article-title":"Decision making and cancer","volume":"70","author":"Reyna","year":"2015","journal-title":"Am Psychol"},{"key":"10.1016\/j.ejca.2022.11.036_bib155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.breast.2018.05.009","article-title":"Development and pilot testing of a Decision Aid (DA) for women with early-stage breast cancer considering contralateral prophylactic mastectomy","volume":"40","author":"Ager","year":"2018","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.ejca.2022.11.036_bib156","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1097\/SLA.0000000000004574","article-title":"The role of emotion in cancer surgery decisions: applying concepts from decision psychology","volume":"273","author":"Lee","year":"2021","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.ejca.2022.11.036_bib157","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1002\/cam4.2914","article-title":"Differences in physician opinions about controversial issues surrounding contralateral prophylactic mastectomy (CPM): a survey of physicians from accredited breast centers in the United States","volume":"9","author":"Yao","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2022.11.036_bib158","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fonc.2018.00647","article-title":"Plastic and reconstructive surgeons' knowledge and comfort of contralateral prophylactic mastectomy: a survey of the American Society of Plastic Surgeons","volume":"8","author":"Lopez","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2022.11.036_bib159","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/SAP.0000000000001661","article-title":"The influence of patient exposure to breast reconstruction approaches and education on patient choices in breast cancer treatment","volume":"83","author":"Dobke","year":"2019","journal-title":"Ann Plast Surg"},{"issue":"1","key":"10.1016\/j.ejca.2022.11.036_bib160","doi-asserted-by":"crossref","first-page":"498","DOI":"10.21037\/gs.2020.03.15","article-title":"Contralateral prophylactic mastectomy and implications for breast reconstruction","volume":"10","author":"Santosa","year":"2021","journal-title":"Gland Surg"},{"issue":"3","key":"10.1016\/j.ejca.2022.11.036_bib161","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10549-016-4076-5","article-title":"The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence","volume":"161","author":"Janz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2022.11.036_bib162","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S0960-9776(19)31126-9","article-title":"Is prophylactic mastectomy justified in women without BRCA mutation?","volume":"48","author":"Rutgers","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2022.11.036_bib163","unstructured":"European Commission Initiative on Breast Cancer. Inviting and informing women about screening. Available at: https:\/\/healthcare-quality.jrc.ec.europa.eu\/european-breast-cancer-guidelines\/Invitation-to-screening-and-decision-aid; 2021. [Accessed 9 January 2022]."},{"issue":"5","key":"10.1016\/j.ejca.2022.11.036_bib164","doi-asserted-by":"crossref","first-page":"936e","DOI":"10.1097\/PRS.0000000000005523","article-title":"Breast cancer knowledge and decisions made for contralateral prophylactic mastectomy: a survey of surgeons and women in the general population","volume":"143","author":"Hooper","year":"2019","journal-title":"Plast Reconstr Surg"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:59Z","timestamp":1760733599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922017877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":161,"alternative-id":["S0959804922017877"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.036","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}